Pioneering immunotherapy shows promise in type 1 diabetes

August 9, 2017
Graphic explaining peptide immunotherapy for type 1 diabetes. Credit: Carla Schaffer / M.A. Ali et al., / AAAS

It may be possible to 'retrain' the immune system to slow the progression of type 1 diabetes, according to results of a clinical trial published today in the journal Science Translational Medicine.

Researchers leading the MonoPepT1De trial at King's College London and Cardiff University observed noticeable changes in the behaviour of the immune systems of type 1 patients that had been injected with peptides, small fragments of the protein molecules found in the beta cells of the pancreas.

Type 1 diabetes develops when a patient's immune system mistakenly attacks the insulin producing beta cells in the pancreas. Without treatment the number of beta cells will slowly decrease and the body will no longer be able to maintain (blood glucose) levels.

The trial was led by Professor Mark Peakman, whose work is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Guy's and St Thomas' NHS Foundation Trust and King's College London, and who says: "When someone is diagnosed with type 1 diabetes they still typically have between 15% and 20% of their . We wanted to see if we could protect these remaining cells by retraining the immune system to stop attacking them."

"We still have a long way to go, but these early results suggest we are heading in the right direction. The peptide technology used in our trial is not only appears to be safe for patients at this stage, but it also has a noticeable effect on the immune system."

There is currently no cure for type 1 diabetes, which can affect major organs in the body, including the heart, blood vessels, nerves, eyes and kidneys. The UK has one of the highest rates of type 1 diabetes in the world with 400,000 people currently living with the condition.

"It was encouraging to see that people who receive the treatment needed less insulin to control their levels, suggesting that their pancreas was working better" commented, Prof Colin Dayan from Cardiff University, the clinical Chief Investigator for the study

The study was also supported by Diabetes UK and JDRF, the Type 1 diabetes charity.

Dr Elizabeth Robertson, Director of Research at Diabetes UK, the charity who supported the lead author of the study, said: "Diabetes UK is committed to increasing our understanding of the immune attack in type 1 diabetes and finding ways to stop it. These new findings are an exciting step towards immunotherapies being used to prevent this serious condition from developing in those at high risk, or stop it from progressing in those already diagnosed."

Karen Addington is UK Chief Executive of the type 1 diabetes charity JDRF which funded the research, said: "Exciting immunotherapy research like this increases the likelihood that one day insulin-producing cells can be protected and preserved. That would mean people at risk of Type 1 diabetes might one day need to take less insulin, and perhaps see a future where no one would ever face daily injections to stay alive."

Following the success of the MonoPepT1De trial, which was supported by the NIHR BRC at Guy's and St Thomas' and King's College London, King's and UCB Biopharma (a Belgian Biopharmaceutical company) are collaborating on a next generation product - MultipepT1De - in a Phase 1b safety study.

UCB has acquired exclusive licenses from King's College London to MonopepT1De and MultipepT1De worldwide.

Explore further: New immunotherapy trial for Type 1 diabetes

More information: M. Alhadj Ali el al., "Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes," Science Translational Medicine (2017). stm.sciencemag.org/lookup/doi/ … scitranslmed.aaf7779

Related Stories

New immunotherapy trial for Type 1 diabetes

March 25, 2016
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy's Hospital in London.

Insulin release is controlled by the amount of Epac2A at the secretory vesicles

July 7, 2017
Specialized beta cells in the pancreas release the hormone insulin to control our blood glucose levels, and failure of this mechanism is central to the development of type-2 diabetes. How much and when insulin is released ...

Many diabetes patients produce some insulin

June 22, 2017
Some insulin is still produced in almost half of patients that have had type 1 diabetes for more than ten years. The study conducted by researchers at Uppsala University in Sweden has now been published online by the medical ...

An inexpensive first-line treatment for type 2 diabetes may also reduce heart disease in those with type 1 diabetes

June 12, 2017
An inexpensive first-line treatment for type 2 diabetes may also reduce heart disease in those with type 1 diabetes, according to a new global trial led by the University of Glasgow.

Protein packaging may cause the immune attacks of type 1 diabetes

November 21, 2016
Type-1 diabetes occurs when immune cells attack the pancreas. EPFL scientists have now discovered what may trigger this attack, opening new directions for treatments.

Scientists study how some insulin-producing cells survive in type 1 diabetes

February 9, 2017
A Yale-led research team identified how insulin-producing cells that are typically destroyed in type 1 diabetes can change in order to survive immune attack. The finding may lead to strategies for recovering these cells in ...

Recommended for you

Personalized blood sugar goals can save diabetes patients thousands

December 11, 2017
A cost analysis by researchers at the University of Chicago Medicine shows treatment plans that set individualized blood sugar goals for diabetes patients, tailored to their age and health history, can save $13,546 in health ...

Kidney disease increases risk of diabetes, study shows

December 11, 2017
Diabetes is known to increase a person's risk of kidney disease. Now, a new study from Washington University School of Medicine in St. Louis suggests that the converse also is true: Kidney dysfunction increases the risk of ...

Type 2 diabetes is not for life

December 5, 2017
Almost half of the patients with Type 2 diabetes supported by their GPs on a weight loss programme were able to reverse their diabetes in a year, a study has found.

Skipping breakfast disrupts 'clock genes' that regulate body weight

November 30, 2017
Irregular eating habits such as skipping breakfast are often associated with obesity, type 2 diabetes, hypertension and cardiovascular disease, but the precise impact of meal times on the body's internal clock has been less ...

Type 2 diabetes has hepatic origins

November 28, 2017
Affecting as many as 650 million people worldwide, obesity has become one of the most serious global health issues. Among its detrimental effects, it increases the risk of developing metabolic conditions, and primarily type ...

Critical link between obesity and diabetes has been identified

November 28, 2017
UT Southwestern researchers have identified a major mechanism by which obesity causes type 2 diabetes, which is a common complication of being overweight that afflicts more than 30 million Americans and over 400 million ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.